JP2003520272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520272A5 JP2003520272A5 JP2001553267A JP2001553267A JP2003520272A5 JP 2003520272 A5 JP2003520272 A5 JP 2003520272A5 JP 2001553267 A JP2001553267 A JP 2001553267A JP 2001553267 A JP2001553267 A JP 2001553267A JP 2003520272 A5 JP2003520272 A5 JP 2003520272A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkylene
- optionally
- cycloalkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 22
- -1 methoxy, ethoxy Chemical group 0.000 claims 20
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000001153 fluoro group Chemical group F* 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 206010012335 Dependence Diseases 0.000 claims 4
- 206010034912 Phobia Diseases 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000008673 vomiting Effects 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000019899 phobic disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 102000003141 Tachykinin Human genes 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 108060008037 tachykinin Proteins 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- CRQCBBCSYKAPDW-UHFFFAOYSA-N 2-(4-bromo-2,6-dimethylphenoxy)-6-methyl-4-(pentan-3-ylamino)pyridine-3-carbonitrile Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Br)=CC=2C)C)=C1C#N CRQCBBCSYKAPDW-UHFFFAOYSA-N 0.000 claims 1
- DVPXGVDTNQUZJL-UHFFFAOYSA-N 2-(4-bromo-2-methoxyphenoxy)-6-methyl-4-(pentan-3-ylamino)pyridine-3-carbonitrile Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Br)=CC=2)OC)=C1C#N DVPXGVDTNQUZJL-UHFFFAOYSA-N 0.000 claims 1
- HXHYJQGOWDOAQL-UHFFFAOYSA-N 2-(4-bromo-2-methoxyphenoxy)-6-methyl-4-(pentan-3-ylamino)pyridine-3-carboxamide Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Br)=CC=2)OC)=C1C(N)=O HXHYJQGOWDOAQL-UHFFFAOYSA-N 0.000 claims 1
- GATYVUUKXLTIJT-UHFFFAOYSA-N 2-(4-chloro-2,6-dimethylphenoxy)-3,6-dimethyl-n-pentan-3-ylpyridin-4-amine Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C GATYVUUKXLTIJT-UHFFFAOYSA-N 0.000 claims 1
- PBZWSSIFISEGAS-UHFFFAOYSA-N 2-(4-chloro-2,6-dimethylphenoxy)-4-(1-hydroxybutan-2-ylamino)-n,6-dimethylpyridine-3-carboxamide Chemical compound CCC(CO)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C(=O)NC PBZWSSIFISEGAS-UHFFFAOYSA-N 0.000 claims 1
- CWYGPMSXGZKRIP-UHFFFAOYSA-N 2-(4-chloro-2,6-dimethylphenoxy)-4-(1-methoxybutan-2-ylamino)-6-methylpyridine-3-carboxamide Chemical compound COCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C(N)=O CWYGPMSXGZKRIP-UHFFFAOYSA-N 0.000 claims 1
- NJRJOSPWGJQYIE-UHFFFAOYSA-N 2-(4-chloro-2,6-dimethylphenoxy)-4-(1-methoxybutan-2-ylamino)-n,6-dimethylpyridine-3-carboxamide Chemical compound COCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C(=O)NC NJRJOSPWGJQYIE-UHFFFAOYSA-N 0.000 claims 1
- BJILKEUBIUCVAS-UHFFFAOYSA-N 2-(4-chloro-2,6-dimethylphenoxy)-4-(2-methoxypentan-3-ylamino)-6-methylpyridine-3-carboxamide Chemical compound COC(C)C(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C(N)=O BJILKEUBIUCVAS-UHFFFAOYSA-N 0.000 claims 1
- UFMFUXYHEUAHHY-UHFFFAOYSA-N 2-(4-chloro-2,6-dimethylphenoxy)-4-(2-methoxypentan-3-ylamino)-n,6-dimethylpyridine-3-carboxamide Chemical compound COC(C)C(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C(=O)NC UFMFUXYHEUAHHY-UHFFFAOYSA-N 0.000 claims 1
- JLGFGKMKPSXEQE-UHFFFAOYSA-N 2-[4-chloro-2-(trifluoromethoxy)phenoxy]-6-methyl-4-(pentan-3-ylamino)pyridine-3-carboxamide Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2)OC(F)(F)F)=C1C(N)=O JLGFGKMKPSXEQE-UHFFFAOYSA-N 0.000 claims 1
- HPDGHEAXAFGTGP-UHFFFAOYSA-N 2-[4-chloro-2-(trifluoromethoxy)phenoxy]-N,6-dimethyl-4-(pentan-3-ylamino)pyridine-3-carboxamide Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2)OC(F)(F)F)=C1C(=O)NC HPDGHEAXAFGTGP-UHFFFAOYSA-N 0.000 claims 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 1
- ZPSJLQMQKUVCKZ-UHFFFAOYSA-N 4-(3,6-dimethyl-4-pentan-3-yloxypyridin-2-yl)oxy-3,5-dimethylbenzamide Chemical compound CCC(CC)OC1=CC(C)=NC(OC=2C(=CC(=CC=2C)C(N)=O)C)=C1C ZPSJLQMQKUVCKZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 claims 1
- 108091005479 5-HT2 receptors Proteins 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 101800003906 Substance P Proteins 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010061592 cardiac fibrillation Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000002600 fibrillogenic effect Effects 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000000971 hippocampal effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229960001078 lithium Drugs 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- NIOMSWGSBCFSGQ-UHFFFAOYSA-N methyl 2-(4-chloro-2,6-dimethylphenoxy)-6-methyl-4-(1-methylsulfanylbutan-2-ylamino)pyridine-3-carboxylate Chemical compound CSCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2C)C)=C1C(=O)OC NIOMSWGSBCFSGQ-UHFFFAOYSA-N 0.000 claims 1
- XYNCUNGGOOWKHL-UHFFFAOYSA-N methyl 2-(4-chloro-2,6-dimethylphenoxy)-6-methyl-4-(oxolan-3-ylamino)pyridine-3-carboxylate Chemical compound C1=C(C)N=C(OC=2C(=CC(Cl)=CC=2C)C)C(C(=O)OC)=C1NC1CCOC1 XYNCUNGGOOWKHL-UHFFFAOYSA-N 0.000 claims 1
- UEGLRPIPCOFFEI-UHFFFAOYSA-N methyl 2-[4-chloro-2-(trifluoromethoxy)phenoxy]-6-methyl-4-(pentan-3-ylamino)pyridine-3-carboxylate Chemical compound CCC(CC)NC1=CC(C)=NC(OC=2C(=CC(Cl)=CC=2)OC(F)(F)F)=C1C(=O)OC UEGLRPIPCOFFEI-UHFFFAOYSA-N 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000004693 neuron damage Effects 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000037324 pain perception Effects 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960002601 protriptyline Drugs 0.000 claims 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 229960003991 trazodone Drugs 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 1
- 229960002431 trimipramine Drugs 0.000 claims 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17661100P | 2000-01-18 | 2000-01-18 | |
| US60/176,611 | 2000-01-18 | ||
| PCT/IB2001/000004 WO2001053263A1 (en) | 2000-01-18 | 2001-01-05 | Corticotropin releasing factor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003520272A JP2003520272A (ja) | 2003-07-02 |
| JP2003520272A5 true JP2003520272A5 (enExample) | 2005-08-25 |
Family
ID=22645084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001553267A Pending JP2003520272A (ja) | 2000-01-18 | 2001-01-05 | コルチコトロピン放出因子アンタゴニスト |
Country Status (36)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956047B1 (en) * | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| EP1449532A1 (en) * | 1999-08-27 | 2004-08-25 | Pfizer Products Inc. | Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist |
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
| AR040456A1 (es) | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
| EP1688408A3 (en) * | 2002-08-08 | 2007-08-22 | Amgen, Inc | Vanilloid receptor ligands and their use in treatments |
| TW200410945A (en) * | 2002-08-08 | 2004-07-01 | Amgen Inc | Vanilloid receptor ligands and their use in treatments" |
| RS20050532A (sr) | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| EP1583531B1 (en) * | 2003-01-16 | 2007-04-18 | SB Pharmco Puerto Rico Inc | Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US7030145B2 (en) | 2003-04-18 | 2006-04-18 | Bristol-Myers Squibb Company | Pyridinyl derivatives for the treatment of depression |
| US7112585B2 (en) | 2003-04-18 | 2006-09-26 | Bristol-Myers Squibb Company | Pyrimidine derivatives as corticotropin releasing factor inhibitors |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| JP2007517793A (ja) * | 2004-01-06 | 2007-07-05 | 大正製薬株式会社 | 環状アミノ基によって置換されたチエノピリミジン及びチエノピリジン誘導体 |
| US20050171095A1 (en) * | 2004-01-06 | 2005-08-04 | Pfizer Inc | Combination of CRF antagonists and 5-HT1B receptor antagonists |
| JP2007522233A (ja) | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
| MY139645A (en) | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
| AP2006003771A0 (en) | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| AU2005245389A1 (en) * | 2004-05-12 | 2005-12-01 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| JP4958787B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体 |
| US7301022B2 (en) | 2005-02-15 | 2007-11-27 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US8153791B2 (en) | 2005-12-21 | 2012-04-10 | Janssen Pharmaceutica N.V. | Substituted pyrimidinyl oxime kinase inhibitors |
| WO2007109783A2 (en) * | 2006-03-23 | 2007-09-27 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
| GEP20125425B (en) | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| WO2009144632A1 (en) * | 2008-05-30 | 2009-12-03 | Pfizer Limited | Novel compounds |
| GB0913636D0 (en) * | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| PE20160664A1 (es) | 2013-06-27 | 2016-07-09 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| MX376835B (es) | 2015-03-06 | 2025-03-07 | Pharmakea Inc | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. |
| US10766860B2 (en) | 2015-03-06 | 2020-09-08 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CN109415369B (zh) * | 2016-07-08 | 2021-12-07 | 豪夫迈·罗氏有限公司 | 稠合嘧啶衍生物 |
| EP3510029B1 (en) * | 2016-09-07 | 2025-11-05 | The Regents of The University of California | Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition |
| SG11201901999XA (en) | 2016-09-07 | 2019-04-29 | Pharmakea Inc | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| KR20230162996A (ko) | 2016-09-07 | 2023-11-29 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| AU2018235561B2 (en) | 2017-03-13 | 2020-06-18 | Asahi Kasei Pharma Corporation | Tetrahydroquinoline derivatives as P2X7 receptor antagonists |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| WO2020168068A1 (en) * | 2019-02-13 | 2020-08-20 | The University Of Vermont And State Agricultural College | Small molecule antagonist to pacap receptor and uses thereof |
| EP4054608B1 (en) * | 2019-11-06 | 2026-03-04 | Albert Einstein College of Medicine | Small molecule prostagladin transport inhibitors |
| EP4604945A2 (en) * | 2022-10-18 | 2025-08-27 | Merck Sharp & Dohme LLC | Novel kv3 channel modulators |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3145287A1 (de) | 1981-11-14 | 1983-05-19 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| EP0264883A3 (en) | 1986-10-21 | 1990-04-04 | Banyu Pharmaceutical Co., Ltd. | Substituted pyridine derivatives |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| CA2051012C (en) | 1990-09-14 | 2002-04-02 | David R. Borcherding | Carbocyclic adenosine analogs useful as immunosupressants |
| DE59303950D1 (de) | 1992-08-10 | 1996-10-31 | Volkswagen Ag | Schalteinrichtung für ein Getriebe |
| BR9307646A (pt) * | 1992-12-17 | 1999-05-25 | Pfizer | Pirrolopirimidinas como antagonistas de crf |
| JP3398152B2 (ja) * | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| PA8467401A1 (es) * | 1998-02-17 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para tratar la insuficiencia cardiaca |
| US6130188A (en) * | 1998-05-05 | 2000-10-10 | American Cyanamid Company | Herbicidal pyridine compounds |
| EP1040831A3 (en) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| US6387894B1 (en) * | 1999-06-11 | 2002-05-14 | Pfizer Inc. | Use of CRF antagonists and renin-angiotensin system inhibitors |
-
2001
- 2001-01-05 CA CA002397633A patent/CA2397633A1/en not_active Abandoned
- 2001-01-05 JP JP2001553267A patent/JP2003520272A/ja active Pending
- 2001-01-05 EA EA200300834A patent/EA200300834A1/ru unknown
- 2001-01-05 AP APAP/P/2002/002583A patent/AP2002002583A0/en unknown
- 2001-01-05 EP EP01900209A patent/EP1263732A1/en not_active Withdrawn
- 2001-01-05 AU AU23905/01A patent/AU779995B2/en not_active Ceased
- 2001-01-05 SK SK1006-2002A patent/SK10062002A3/sk unknown
- 2001-01-05 EA EA200200688A patent/EA200200688A1/ru unknown
- 2001-01-05 EE EEP200200400A patent/EE200200400A/xx unknown
- 2001-01-05 MX MXPA02007047A patent/MXPA02007047A/es unknown
- 2001-01-05 HU HU0204272A patent/HUP0204272A3/hu unknown
- 2001-01-05 WO PCT/IB2001/000004 patent/WO2001053263A1/en not_active Ceased
- 2001-01-05 HR HR20020599A patent/HRP20020599A2/hr not_active Application Discontinuation
- 2001-01-05 KR KR1020027009229A patent/KR20020063934A/ko not_active Ceased
- 2001-01-05 CZ CZ20022390A patent/CZ20022390A3/cs unknown
- 2001-01-05 PL PL01357589A patent/PL357589A1/xx not_active Application Discontinuation
- 2001-01-05 YU YU54402A patent/YU54402A/sh unknown
- 2001-01-05 OA OA1200200206A patent/OA12157A/en unknown
- 2001-01-05 CN CN01803846A patent/CN1395566A/zh active Pending
- 2001-01-05 IL IL15063201A patent/IL150632A0/xx unknown
- 2001-01-05 BR BR0107662-0A patent/BR0107662A/pt not_active IP Right Cessation
- 2001-01-12 HN HN2001000006A patent/HN2001000006A/es unknown
- 2001-01-16 AR ARP010100176A patent/AR027221A1/es not_active Application Discontinuation
- 2001-01-16 PE PE2001000038A patent/PE20011166A1/es not_active Application Discontinuation
- 2001-01-17 US US09/761,995 patent/US6833378B2/en not_active Expired - Fee Related
- 2001-01-17 TN TNTNSN01008A patent/TNSN01008A1/fr unknown
- 2001-01-17 GT GT200100007A patent/GT200100007A/es unknown
- 2001-01-17 CO CO01003117A patent/CO5271658A1/es not_active Application Discontinuation
- 2001-01-18 UY UY26544A patent/UY26544A1/es not_active Application Discontinuation
- 2001-01-18 PA PA20018510001A patent/PA8510001A1/es unknown
- 2001-01-22 SV SV2001000289A patent/SV2002000289A/es not_active Application Discontinuation
-
2002
- 2002-06-20 BG BG106853A patent/BG106853A/bg unknown
- 2002-06-25 IS IS6445A patent/IS6445A/is unknown
- 2002-07-08 CR CR6698A patent/CR6698A/es not_active Application Discontinuation
- 2002-07-11 MA MA26728A patent/MA26864A1/fr unknown
- 2002-07-16 ZA ZA200205660A patent/ZA200205660B/en unknown
- 2002-07-17 NO NO20023424A patent/NO20023424L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200205660B (en) | Corticotropin releasing factor antagonists. | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| EP0960106B1 (en) | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4) | |
| JP2005047930A5 (enExample) | ||
| RU2544011C2 (ru) | Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний | |
| IL271290B1 (en) | Dihydro-pyrrolo-pyridine derivatives | |
| JPWO2020017587A1 (ja) | ピリダジノン誘導体 | |
| JP2008513413A5 (enExample) | ||
| RU2002131885A (ru) | Антраниламиды и их применение в качестве лекарственных средств | |
| JP2007520435A (ja) | 抗癌剤としてのピリジノ［１，２−ａ］ピリミジン−４−オン化合物 | |
| EP1379507A1 (en) | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | |
| JPH10511114A (ja) | 新規なｎ−アミノアルキルフルオレンカルボキサミド；新規な種類のドーパミンリセプタ亜型特異性リガンド | |
| RU2003121307A (ru) | (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета | |
| CA2251989A1 (en) | Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor subtype specific ligands | |
| JP2003513066A5 (enExample) | ||
| CA2326611C (en) | Substituted heterocyclic derivatives | |
| JPH08500338A (ja) | 貧血治療のためのピラゾロピリジン化合物 | |
| RU96124804A (ru) | Производные хинолина как антагонисты nk, рецептора тахикинина | |
| JP3041834B2 (ja) | Ｎ―アミノアルキル―２―アントラキノンカルボキサミド；ドーパミンレセプターサブタイプに特異的な新しい配位子 | |
| BR0103180A (pt) | Derivados do diazabiciclooctano e suas utilizações terapêuticas | |
| KR20010013387A (ko) | 통증을 치료하기 위한 드라플라진-유사체의 용도 | |
| KR100307845B1 (ko) | 신규한n-아미노알킬-1-비페닐렌일-2-카르복스아미드신규한도파민수용체서브타입특이적리간드 | |
| SK126799A3 (en) | Isoquinolyl-benzamide derivatives, process for their production, pharmaceutical composition containing them and their use | |
| JP5248585B2 (ja) | 治療薬としてのニコチンアミド誘導体およびそれらの使用 | |
| EP0369810A2 (en) | PAF antagonists as anti-hyperendothelinemia agents |